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Abstract: 
Motivation: Rhodopsin is a visual pigment present in rod cells of retina. It belongs to GPCR family and involves 
photoisomerization of 11-cis-retinal to all-trans-retinal isomers, conformational changes in rhodopsin and signal transduction 
cascade to generate a nerve impulse. This signaling pathway has been targeted to eliminate the effect of a mutation (Gly90ÆAsp) 
responsible for abnormal activation of G-protein without retinal conformations in the absence of light leading to congenital night 
blindness. A theoretical model of rhodopsin with induced mutation has been deliberated in order to find potential ligands which 
can offset this mutational effect. The binding interactions between the target mutated rhodopsin model and potential ligands have 
been predicted with the help of molecular docking. The results indicated strong functional benefits of ligands as an inhibitor and 
an agonist for mutated rhodopsin model. Therefore, we propose a new visual cascade model which can initiate the normal 
signaling of rhodopsin mutant with the help of proposed ligands and can provide a hope for vision in future. 
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Background: 
Rhodopsin is a visual pigment belonging to G-coupled Protein 
Receptor family (GPCR). It has seven transmembrane α-helix 
structure containing six loops and present in rod cells of retina. 
It has two building blocks; one is opsin protein called scotopsin 
and second is a cofactor known as Retinal [1]. The role of GPCR 
as extracellular ligand-binding proteins makes them attractive 
targets for drug design. GPCRs account for approximately 40% 
of all therapeutic intervention, and major GPCR research 
projects are found throughout the pharmaceutical industry [2, 
3]. Molecular study of the protein progresses in the field of 
“Docking” which refers to the potential binding of 
macromolecules with each other in a favorable manner. The 
binding of agonist with GPCR proteins cause conformational 
changes in its structure. If a receptor in an active state 
encounters a G-protein, it may activate it. The binding of G 
proteins to receptor affect the receptor's affinity for ligands. By 
binding suitable agonists, protein functionality can be enhanced 
[4]. Signal messages start by ligand binding to a GPCR’s 
extracellular region which triggers changes in the protein’s 
transmembrane region. This causes the release of guanosine 
diphosphate (GDP) and the uptake of guanosine triphosphate 
(GTP) from the G-protein (transducin), stimulating the 
activation of signaling pathway.  
 
A mutational effect in human rhodopsin has been studied for 
night blindness i.e. Gly-90ÆAsp mutation on the second 
transmembrane helix, places an extra negative charge in the 
opsin pocket, which could contribute to partial deprotonation 
of the retinal Schiff base and increase photoreceptor noise. In 
vitro experiments suggest that transducin is activated by the 
Gly-90ÆAsp mutation in the absence of both the retinal 
chromophore and light, which is termed as "constitutive 
activity"  [5]. There is no treatment for this abnormality yet; BIOINFORMATION  open access 
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therefore, it requires attention and need to explore possible 
remedies by applying drug designing techniques like docking 
and for this purpose, potential drug targets are to be 
discovered. One of the important classes of known inhibitors 
for rhosopsin is arrestin. Arrestins are a family of protein that is 
important for regulating signal transduction within cells. The 
phosphorylated receptor can be linked to arrestin molecules 
that prevent it from binding and activating G-protein, 
effectively switching it off for a short period of time. This 
mechanism is used to study rhodopsin in retina cells to 
compensate for exposure to light [6]. A model of interaction for 
the human Arrestin-Rhodopsin complex has been obtained by a 
protein docking approach, reinforced by experimental data and 
binding energy calculation [7]. The beta-arrestin molecules are 
found to have inhibitory action on G-protein and are involved 
in signaling/desensitization process. Several other companies 
including 7TM, a GPCR-focused drug company, and Perkin-
Elmer have developed GPCR screening technologies that take 
advantage of the arrestin–receptor binding [8].  
 
Another important class of known agonists for rhosopdin is 
cyanidin compounds. Cyanidin belongs to the group of 
anthocyanins (C6-C3-C6 structure) found in most red coloured 
berries such as bilberry, blackberry, and raspeberry. The Visual 
acuity can be improved through administration of anthocyanin 
pigments to animal and humans as well to enhance the night 
vision [9, 10]. Three anthocyanins from black currant stimulated 
regeneration of rhodopsin and formation of regeneration 
intermediate was accelerated by cyanidin 3-rutinoside [10, 11]. 
These studies strongly reveal the fact that enhancement of 
rhodopsin regeneration is a mechanism by which anthocyanins 
enhance visual acuity. It has been studied and observed that the 
effects of different cyanidin compounds, like cyanidin 3-
glycosides, glucoside and rutinoside, stimulate the regeneration 
of rhodopsin. The formation of regeneration intermediate was 
suggested to be accelerated by cyanidin 3-rutinoside [11]. The 
binding affinity of this important organic molecule with 
rhodopsin is yet to be predicted and analyzed through docking 
approach. 
 
Methodology: 
Bioinformatics approach and tools have been used to carry out 
this research as mentioned in the flow chart in (Figure 1).     
 
 
Figure 1: Flow chart of the methodology for molecular docking. 
 
Target Mutant Receptor Macromolecule 
A theoretical model of human rhodopsin protein has been 
obtained by homology modeling approach because it shows 
93% similarity with bovine rhodopsin templates. This model 
has been refined and used further for docking as recommended 
[12]. A missense mutation; GLY-90 transformed ASP, is induced 
in the model with the help of Swiss PDB Viewer [13]. The 
structure of rhodopsin holds retinal molecule as its native 
ligand. Therefore, the theoretical model of rhodopsin along 
with its natural ligand was considered in order to conserve its 
conformational space during docking. The PDB structure of Cis-
retinal was retrieved from online virtual chemistry laboratory 
[14]. 
 
Macromolecule Binding Pocket Prediction 
The receptor macromolecule was first analyzed thoroughly for 
the possibility of existence of cavities and spaces which are 
necessary for the presence of native reactive groups and atoms 
involved in interactions with external ligands and facilitate their 
docking. For this purpose, the binding pockets of the mutant 
rhodopsin model were predicted by Pocket-Finder [15]. It 
searches and predicts top 10 potential binding sites for ligands 
and residues in close contact. 
 
Ligand Structural Resources 
Beta arrestin was chosen for its inhibitory property against 
rhodopsin signaling. The crystal structure of bovine beta-
arrestin (PDB: 1G4R), comprising of 393 amino acids, at 1.9A 
was taken from Protein Data Bank [16]. Cyanidin 3-rutinoside is 
another vital chemical ligand which is used for its agonistic 
property against rhodopsin. Its structure was sketched (Figure 
2) in Accelrys Draw 4.0 [17] and converted to PDB format for 
docking by using UCSF Chimera [18]. 
 
 
Figure 2: Structure of cyanidin 3-rutinoside sketched in 
Accelrys Draw 4.0.  
 
Molecular Docking and Energy Computations  
Molecular docking of the structures of receptor macromolecule 
and its potential ligands was done by Hex 4.5 [19] and 
AutoDockTools [20]. Hex 4.5 performs macromolecular docking 
by using Spherical Polar Fourier (SPF) correlations in order to 
calculate total energy values (Etotal) of the docked complexes. It BIOINFORMATION  open access 
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provides user friendly graphical environment to visualize the 
docked complexes and animated form of total poses performed 
during docking.  
 
Prediction of Binding Interactions of Complexes  
The binding interactions of the complexes were predicted by 
AutoDockTools [20]. Autodock 4.0 is considered to be one of 
the best known structure based rational drug design program 
which predicts protein-ligand interactions and protein-protein 
interactions. It operates two major tools during the execution of 
docking. One is AutoGrid that computes atomic affinity grid 
maps and other is AutoDock that generates docking complexes. 
Complexes were further analyzed in Python Molecular Viewer 
interface PMV 1.5.2 [20] in order to reveal the binding 
interactions i.e., hydrogen bonds, vander waals forces, 
hydrophobic interactions and energy calculations. 
 
Results: 
The mutant version (GLY90ÆASP) of homology model of 
Human rhodopsin was thoroughly analyzed to find all possible 
binding pockets and close contact residues in the receptor’s 
vicinity with the help of Pocket-Finder Server [15]. It predicted 
top ten binding sites in the structure of rhodopsin, out of which, 
two binding sites have been selected and highlighted with 
maximum cavity and large number of residues in receptor’s 
vicinity (Figure 3). Site 1 has 541 Cubic Angstroms volume and 
contains 29 residues (104 atoms) in binding pocket. It is 
surrounded by close contact resides indicated by ball and stick 
representation in blue color (Figure, 3). Site 2 has 386 Cubic 
Angstroms volume and contains 23 residues (92 atoms) in 
binding pocket. It is surrounded by close contact resides 
indicated by ball and stick representation in purple color 
(Figure 3). Rests of the sites are indicated by gray mesh and 
occupy smaller volume. Therefore, the binding sites 1 and 2 
were considered favorable for the docking of potential ligands. 
 
 
Figure 3: Structure of human rhodopsin protein with ten 
binding pockets (indicated in gray mesh) as predicted by 
Pocket-Finder [15] and visualized in RASMOL 2.7.3.1v [21]. 
 
The prediction of the binding sites facilitates molecular docking. 
The mutant rhodopsin was first docked with its native ligand 
“cis-retinal” so that its native binding pocket can be conserved 
and other candidate ligands can be docked in suitable 
orientation in the predicted binding sites. Cis-retinal was 
docked in binding site 1 (29 residues in close contact) because it 
resides in the vicinity of Helix-VII which is the native binding 
pocket for retinal conformations. The binding interactions of the 
rhodopsin with cis-retinal indicate one hydrogen bond and 
presence of hydrophobic and vander waals interactions with 
rhodopsin  (Figure 6) which is a clear evidence for its native 
affinity with it. This complex was further docked with beta-
arrestin. The results of the interactions showed two hydrogen 
bonds, hydrophobic and vander waals interactions with 
receptor (Figure 7) which shows strong affinity between beta 
arrestin and rhodopsin being similar in nature. Later, rhodopsin 
was docked with cyanidin 3-rutinoside and showed 
hydrophobic and vander waals interactions with rhodopsin 
(Figure 8). The energy computations of the complexes as 
predicted by Hex and ADT have been recorded Table 1 (see 
supplementary material). It has been noticed from Hex results 
that beta-arrestin has least energy (Etotal) than organic 
molecules because beta-arrestin is a protein molecule therefore; 
it has more binding affinity with rhodopsin due to similar 
protein nature. However, binding energy of cyanidin, as 
computed by Hex and ADT, is more or less identical to that of 
retinal. These results lead to successful hypothesis that these 
complexes can work for rhodopsin activation and regeneration 
to initiate the visual process normally. 
 
 
Figure 4: Docked model of mutant Rhodopsin (Blue) bound 
with Cis-retinal (green) and beta-arrestin (red). Image produced 
by using UCSF Chimera 1.5.3 [18]. 
 
Discussion:  
GPCRs undergo multiple conformational changes upon agonist 
binding so new agonist exploration and development is in 
progress possibly through docking techniques [4]. In this study, 
a human rhodopsin mutation (Gly90ÆAsp)  [5] was induced 
and modeled and docked with its potential ligands successively 
in order to propose a cure for the congenital night-blindness. 
The docking interactions of mutant rhodopsin model and beta-
arrestin show close affinity with each other which conforms to 
previous studies conducted on the inhibitory effect of beta 
arrestin on rhodopsin [6, 8]. This is a clear evidence of this 
effective complex that arrestin can work as an inhibitor to BIOINFORMATION  open access 
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switch off the abnormal rhodopsin (Figure 4). However, the 
docking interactions of cyanidin 3-rutinoside with rhodopsin 
are also found effective and favorable to work as agonist for its 
regeneration and activation (Figure 5) which conforms to the 
previous experimental studies conducted on cyanidin 
compounds in order to improve night vision [10, 11]. Therefore, 
both of these ligands prove to have effective role in the 
improvement of night vision. 
 
 
Figure 5: Docked model of mutant Rhodopsin bound with Cis-
retinal (Sticks) and cyanidin 3-rutinoside (Sticks). Image 
produced by using UCSF Chimera 1.5.3 [18]. 
 
 
Figure 6: Detailed view of binding interactions between the 
docked complexes of mutant rhodopsin model with cis-retinal, 
visualized in PMV 1.5.2 [20]. Hydrogen bond between 
LYS296:HZ1 of rhodopsin with 1: O of Cis-retinal is indicated in 
green and hydrophobic and Vander Waals interactions 
indicated in red and gray mesh circles among the receptor 
protein residues in close contact i.e., SER186, LYS296, ALA117, 
THR118, GLU122, HIS211, TYR265, TRP 268, MET107, PHE218 
and PHE212. 
 
Depending on the structural and functional evidences of beta 
arrestin and cyanidin 3-rutinoside, the malfunctioning in the 
rhodopsin visual cascade can be mended. The proposed and 
corrected signaling pathway is described with the help of 
figures. In Figure 4, beta-arrestin molecule binds to the mutated 
rhodopsin and deactivates G-protein by blocking rhodopsin 
receptor site. Arrestin will work for a short period of time and 
deattaches after deactivating G-protein. In Figure 5, cyanidin 
will bind to rhodopsin just near to cis-retinal in Helix-VII and 
help in rhodopsin regeneration in order to enhance signaling. In 
this way retinal will isomerize due to which rhodopsin can 
change conformation to carry out signal transduction cascade 
normally. 
 
 
Figure 7: Detailed view of binding interactions between the 
docked complexes of mutant rhodopsin model with beta -
arrestin, visualized in PMV 1.5.2 [20]. Two hydrogen bonds are 
found between ASN315:HD22 of rhodopsin with 
ARG393:HH22 of beta-arrestin and  ASN326:OD1 of rhodopsin 
with GLU389:O of beta-arrestin as indicated in green while 
hydrophobic and Vander Waals  interactions indicated in red 
and gray mesh circles among the receptor protein residues in 
close contact i.e., ASN315, ARG314, LYS311 and ASN326. 
 
 
Figure 8: Detailed view of binding interactions between the 
docked complexes of mutant rhodopsin model with cyanidin 3-
rutinoside, visualized in PMV 1.5.2 [20]. Hydrophobic and 
Vander Waals  interactions are indicated in red and gray mesh 
circles among the receptor protein residues in close contact i.e., BIOINFORMATION  open access 
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ILE133, MET143, PRO142, TYR 136, VAL218, PHE221and 
ILE217. 
 
Conclusion: 
In this research work, the malfunctioning of visual transduction 
cascade of rhodopsin as a result of a missense mutation has 
been studied. The rhodopsin mutant model was docked with 
two potential ligands. One is beta arrestin molecules which 
bind to rhodopsin to offset the effect of abnormal rhodopsin 
signaling without light and retinal isomerization. After that, 
subsequent docking of cyanidin 3-rutinoside with mutant 
rhodopsin initiates its activation and regeneration to trigger 
normal visual transduction cascade.  This research work will 
help in the structural studies of agonist activation and protein 
inhibition and future drug discovery process including 
prediction of ADME/T (Administration, Distribution, 
Metabolism, and Elimination/Toxicity) of these compounds 
with the help of commercial ADME/T tools and its in vitro 
testing in the molecular laboratories to measure their effects on 
model organisms and drug development for congenital night 
blindness. 
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Supplementry material: 
 
Table 1: Energy calculations of docking complexes of mutant rhodopsin model with Cis retinal, beta-arrestin and cyaniding 3-
rutinoside.  
*mRHO= Mutant Rhodopsin, *ETV = Etotal Value, *ESV= EShape Value, *EFV= Eforce Value, *VSV= Vshape Value, *BE= Binding 
Energy, *LE= Ligand Efficiency, *IE= Intermolecular Energy, *VDW= Vander waals and Hbond desolvation energy, *EE= 
Electrostatic Energy, *TE= Total Energy, *ToE=Torsion Energy, *Hb= Hydrogen Bonds 
 
Docking Complex                           Hex                                                            ADT 
ETV ESV  EFV  VSV  BE  LE IE VDW  EE  TE  ToE  Hb 
mRHO+  Cis Retinal  -140.21 -97.05  -43.16  118.31  -6.95  -0.37  -8.6  -8.46  -0.14  0.0  1.65  1 
mRHO+  Arrestin  -535.61 -624.38  88.77  521.44  -8 370.58  4.94  -3.47  -2.71  -8.19  382.24  2 
mRHO+  Cyanidin 3-rutinoside  -99.60  -75.17  -24.42 103.65  -8.54 -0.21 -9.09  -8.49  -0.15  0.02 0.55  No 